Loading
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Previous close
$32.88
−$0.04 · -0.12%
Regular session · ET · Market data may be delayed.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Day range
Current $32.88
52-week range
Current $32.88
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
52
Fair Value
Sentiment
37
Bearish
Risk
52
Elevated Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Day range
Current $32.88
52-week range
Current $32.88
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 10M USD | 5M USD | 50M USD | — |
| Cost of goods sold | — | 139.14M USD | — | 61.69M USD |
| Gross profit | 10M USD | −134.14M USD | 50M USD | −61.69M USD |
| Research and development | 168.06M USD | 139.14M USD | 60.03M USD | 62.69M USD |
| Selling, general, and administrative | 53.32M USD | 29.75M USD | 17.11M USD | 13.51M USD |
| Operating expenses | 221.39M USD | 29.75M USD | 87.15M USD | 14.51M USD |
| Interest income | 12.15M USD | — | — | — |
| Interest expense | 7.33M USD | — | — | — |
| Depreciation and amortization | 56K USD | 137K USD | 113K USD | 78K USD |
| Operating income | −211.39M USD | −163.89M USD | −37.15M USD | −76.2M USD |
| Net income | −377.74M USD | −156.99M USD | −37.12M USD | −119.28M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$32.00
2.68% downsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI47.38M0.41%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Total Stock Market ETFVTI28.02M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM24.14M0.03%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF13.71M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO8.76M0.06%14.7B USD0.24%$377.54+0.12%
iShares Biotechnology ETFIBB7.94M0.07%10.73B USD0.44%$211.92-0.88%
Schwab U.S. Small-Cap ETFSCHA5.88M0.03%22.93B USD0.03%$34.55+1.01%
Vanguard Russell 2000 ETFVTWO5.02M0.03%17.4B USD0.06%$119.62+0.25%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
